Polaryx Therapeutics, Inc. (PLYX) Stock Profile — Insider Trades & Financials

EPS$-0.20

Market Cap$269.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Alex Yang

CEO & Executive Director

Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Founded: 2014
Employees: 11
Headquarters: Paramus, New Jersey, United States
Website

⚡

Core Efficiency

D/E Ratio?

0.13

📊

Profitability Ratios

Current Ratio?

8.55

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jun 30, 2026 (in 82 days)

Annual Report (10-K) — Estimated

Jun 30, 2026

Predicted10-K

Mar 24, 2026

10-KQ4 202551d after period end

Data Freshness

Financial Data

4 days ago

Latest filing: 2026-03-24

SEC Metadata

17 days ago